Literature DB >> 15374879

Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes.

Kaeng W Lee1, Gregory Y H Lip, Muzahir Tayebjee, William Foster, Andrew D Blann.   

Abstract

Markers of inflammation (eg, interleukin-6 [IL-6]), and endothelial perturbation (von Willebrand factor [VWF], circulating endothelial cells [CECs]) are altered in acute coronary syndromes (ACS). We hypothesized that CECs and IL-6 levels during the first 48 hours of ACS would predict 30-day and 1-year major cardiovascular end points (MACE). A total of 156 patients with ACS were included. Blood was drawn on admission (baseline) and 48 hours later for plasma VWF, IL-6 (both enzyme-linked immunosorbent assay [ELISA]), and CECs (CD146 immunomagnetic separation). CEC phenotyping was performed by indirect immunoperoxidase staining. At 30 days, 48 patients had a MACE, a predicted by baseline and 48-hour CECs and IL-6 levels, 48-hour VWF levels, and by the "admission-48 hour change" (Delta) in CECs, VWF, and IL-6 (all P = .002). On multivariate analysis, 48-hour CECs (P < .001) were the strongest predictor of MACE, followed by DeltaIL-6 (P = .01) and DeltaVWF (P = .048); 48-hour CECs were the only predictor of death (P = .007). At 1 year, 65 patients had MACE, predicted by 48-hour CECs and DeltaIL-6 levels (P < .001); age (P = .046) and 48-hour CECs (P < .001) were the only predictors of death. CECs stained 93% positive for endothelial nitric oxide synthase (eNOS) but were less than 1% positive for CD34, CD36, and CD45 and less than 3% for CD31. Like raised VWF, abnormal CECs and IL-6 levels during the first 48 hours of ACS were strongly associated with 30-day MACE. CECs at 48 hours were the only independent predictor of both death and MACE at 30 days and 1 year, indicating the crucial role of endothelial/vascular damage in ACS pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374879     DOI: 10.1182/blood-2004-03-1106

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

Review 1.  Endothelial cell heterogeneity and atherosclerosis.

Authors:  William C Aird
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

2.  Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed venous blood.

Authors:  Christopher J Boos; Deirdre A Lane; Delene Kang; Patrick K Y Goon; Andrew D Blann; Gregory Y H Lip
Journal:  J Thromb Thrombolysis       Date:  2006-10       Impact factor: 2.300

3.  Proteomics, metabolomics and circulating endothelial progenitor cells in acute coronary syndromes.

Authors:  Patrick K Y Goon; Gregory Y H Lip
Journal:  J Thromb Thrombolysis       Date:  2006-10       Impact factor: 2.300

Review 4.  Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group.

Authors:  Kim A Eagle; Geoffrey S Ginsburg; Kiran Musunuru; William C Aird; Robert S Balaban; Susan K Bennett; Roger S Blumenthal; Shaun R Coughlin; Karina W Davidson; Edward D Frohlich; Philip Greenland; Gail P Jarvik; Peter Libby; Carl J Pepine; Jeremy N Ruskin; Arthur E Stillman; Jennifer E Van Eyk; H Eser Tolunay; Cheryl L McDonald; Sidney C Smith
Journal:  Circulation       Date:  2010-03-30       Impact factor: 29.690

5.  Evaluation of endothelial damage in sepsis-related ARDS using circulating endothelial cells.

Authors:  Mouhamed Djahoum Moussa; Cristina Santonocito; David Fagnoul; Katia Donadello; Olivier Pradier; Pascale Gaussem; Daniel De Backer; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2014-12-16       Impact factor: 17.440

6.  Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis.

Authors:  Saurabh Sethi; Douglas A Simonetto; Soha S Abdelmoneim; Michael B Campion; Irakli Kaloiani; Amy C Clayton; Walter K Kremers; Kevin C Halling; Patrick S Kamath; Jayant Talwalkar; Vijay H Shah
Journal:  J Clin Exp Hepatol       Date:  2012-04-12

7.  Correlative association of interleukin-6 with intima media thickness: a meta-analysis.

Authors:  Bo Zhang; Jing Wang; Yong Xu; Xiao Zhou; Junsong Liu; Jing Xu; Bo Li; Guang Zhi
Journal:  Int J Clin Exp Med       Date:  2015-03-15

8.  Reproducibility of circulating endothelial cell enumeration and activation in children and adolescents.

Authors:  Justin R Ryder; Michael J O'Connell; Kyle D Rudser; Claudia K Fox; Anna N Solovey; Robert P Hebbel; Aaron S Kelly
Journal:  Biomark Med       Date:  2016-04-13       Impact factor: 2.851

9.  Reduction of circulating endothelial cells in peripheral blood of ALS patients.

Authors:  Svitlana Garbuzova-Davis; Robert L Woods; Michael K Louis; Theresa A Zesiewicz; Nicole Kuzmin-Nichols; Kelly L Sullivan; Amber M Miller; Diana G Hernandez-Ontiveros; Paul R Sanberg
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

10.  Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.

Authors:  J D Lickliter; A B Francesconi; G Smith; M Burge; A Coulthard; S Rose; M Griffin; R Milne; J McCarron; T Yeadon; A Wilks; A Cubitt; D K Wyld; P A Vasey
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.